

[159] SCAFFOLDS OF ELECTROSPUN NANOFIBERS FOR SOFT TISSUE REPAIR

Amir Bahar¹, Nora Nseir², ¹ Nurami Medical, ² Nurami Medical LTD

- **Investment Rational**

Nurami Medical is a medical device company with a revolutionary, proprietary nanofiber and sealant technology focused on the soft tissue repair market. Nurami's first product is ArtiFascia® - a Dural repair patch for neurosurgery. Nurami completed preclinical tests and is starting clinical trials in 2018. Nurami is supported by a strong scientific, clinical and industry-oriented team.

- **Business Strategy**

With over 500,000 neurosurgeries that require Dural repair and 7% annual growth, the Dural market is estimated at over \$800MM globally. ArtiFascia's superior performance and low production costs promise reduced costs for medical centers, whereas current end-user price of \$800/patch, ensures high profit margin and quick time to market.

- **Core Technology**

ArtiFascia® is an innovative porous patch made of synthetic medical-grade biodegradable nanofibers combined with a special sealant embedded in the patch. The nanofibers promote tissue regeneration whereas the sealant prevents leakage and bacterial penetration. Current solutions for Dural repair requires a combination of a patch and a Dural sealant, whereas ArtiFascia's technology combines both in a single product.

- **Product Profile/Pipeline**

ArtiFascia has been tested in a battery of animal tests showing excellent performance and biocompatibility. Nurami received a final approval to initiate first-in-human clinical trials in Q1, 2018. Nurami is also working on a next-generation ArtiFascia that will adhere to the tissue without suturing. CE mark and FDA approval are expected by 2020.

- **What's Next?**

Nurami is currently seeking to raise \$5M to receive the CE mark, FDA approval and to continue R&D on a 2nd generation product. Nurami has also started research on other applications for soft tissue repair.